AN2 Therapeutics, Inc. cotiza a 3.60 USD y tiene una capitalización bursátil de $136M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as stu…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.29 | $-0.29 | $-0.31 | — |
| Estimado | $-0.23 | $-0.24 | $-0.22 | $-0.31 |
| Sorpresa | -26.1% | -20.8% | -40.9% | — |
| Métrica | ANTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -66.3% | -40.4% | -25.9% |
| ROA | -56.8% | -32.0% | -24.8% |
| Current Ratio | 6.87 | 2.84 | +4.03 |
| Debt / Equity | — | 0.28 | — |